Mood after surgical menopause

Removed ovaries, chemical menopause on a GnRH agonist, chemotherapy that shut things down, tamoxifen or aromatase inhibitors after breast cancer. Whatever the route, the drop is abrupt rather than gradual, and the mental-health picture reflects that. This is different from natural perimenopause and it deserves its own conversation.

The pattern isn't perimenopause on fast-forward. It's a different curve, with its own risks and its own treatment logic.

The estrogen fall is a cliff, not a slope. After bilateral oophorectomy or a GnRH agonist, circulating estrogen can drop by more than 90% within days. The mood circuits that estrogen was buffering — serotonin, dopamine, GABA — all destabilize at once. This isn't the same as menopause happening slightly early.

Depression and cognitive risk are measurably higher. Multiple cohort studies show a higher rate of depression, anxiety, and cognitive decline after premenopausal oophorectomy without hormone therapy compared with people who reached menopause naturally. This is one of the strongest evidence bases for offering menopausal hormone therapy (MHT) in this group where medically appropriate.

Chemical menopause on GnRH agonists is often add-back territory. GnRH agonists (leuprolide, goserelin) for endometriosis, fibroids or fertility preservation drop estrogen deliberately. 'Add-back' therapy — a small dose of estrogen and progestogen alongside — is designed to keep bones and mood safer, and it works. If nobody has offered it, ask.

Post-cancer treatments narrow the options, they don't remove them. After hormone-sensitive cancers, systemic estrogen may not be on the table, but non-hormonal medications, cognitive behavioural therapy (CBT), and vaginal estrogen (which is largely local) often are. This deserves a menopause-trained oncology conversation, not a shrug.

The grief piece is real, and separate. Losing ovaries, or facing induced menopause young, often carries grief about fertility, body, and timeline. That grief isn't the same as the neurochemical drop, and both deserve attention. Treating one doesn't treat the other.

The first six months matter. Get a real plan in place rather than 'seeing how you go'.

Menopausal hormone therapy (MHT), where it is clinically appropriate. For most people under 45 who have had ovaries removed for non-cancer reasons, systemic estrogen is strongly recommended (often up to at least age 51) for bone, cardiovascular and mental-health reasons. If you were sent home without a plan, that's a gap to close with a menopause-trained doctor or specialist.

SSRIs or SNRIs as either bridge or long-term. Well-evidenced first line for post-surgical mood symptoms, especially where estrogen isn't an option. Venlafaxine, escitalopram and paroxetine all have supportive trial data.

Ask about testosterone, especially for libido and flatness. The ovaries make testosterone too, and losing them lowers it. A cautious trial of transdermal testosterone (where regulated) can help libido, energy and mood in a meaningful minority. Under specialist care, not a DIY.

Therapy from someone who understands induced menopause. Someone who won't blame everything on hormones, and won't dismiss the hormonal piece either. Trauma-informed and grief-literate matter here more than in natural perimenopause.

Sleep protection isn't optional. The first weeks after surgery or the first cycle on a GnRH agonist wreck sleep for most people. Every mood symptom rides on it. Cool room, no alcohol, and a real conversation about short-term sleep support with your prescriber.

Community with people who've done this. Reading someone who had a bilateral salpingo-oophorectomy at 38 and came out the other side changes what feels possible. The internet has good communities here. So does asking your surgeon who they'd trust.